🟢 Alpha Cognition is trading 6% up today with no confirmed company-specific catalyst

Alpha Cognition is trading 6.09% higher at $9.23, with no direct company-specific catalyst identified for October 2.

• On October 1, the company announced initial CONVERGE real-world evidence findings for ZUNVEYL, including higher therapeutic-dose attainment than generic comparators.
• The S&P 500 is up 0.70% and the Nasdaq Composite is up 1.15% as weaker September jobs data lifted rate-cut hopes. The market backdrop may have contributed, but the cause of this individual move is unconfirmed.